DE69935720D1 - Diamino-propanol-verbindungen zur behandlung von ischaemien - Google Patents

Diamino-propanol-verbindungen zur behandlung von ischaemien

Info

Publication number
DE69935720D1
DE69935720D1 DE69935720T DE69935720T DE69935720D1 DE 69935720 D1 DE69935720 D1 DE 69935720D1 DE 69935720 T DE69935720 T DE 69935720T DE 69935720 T DE69935720 T DE 69935720T DE 69935720 D1 DE69935720 D1 DE 69935720D1
Authority
DE
Germany
Prior art keywords
treatment
ischemas
diamino
galt
propanol compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69935720T
Other languages
English (en)
Other versions
DE69935720T2 (de
Inventor
Subroto Chatterjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE69935720D1 publication Critical patent/DE69935720D1/de
Application granted granted Critical
Publication of DE69935720T2 publication Critical patent/DE69935720T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE69935720T 1998-07-27 1999-07-22 Diamino-propanol-verbindungen zur behandlung von ischaemien Expired - Fee Related DE69935720T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9429898P 1998-07-27 1998-07-27
US94298P 1998-07-27
PCT/US1999/016667 WO2000006145A1 (en) 1998-07-27 1999-07-22 Methods for treating conditions modulated by lactosylceramide

Publications (2)

Publication Number Publication Date
DE69935720D1 true DE69935720D1 (de) 2007-05-16
DE69935720T2 DE69935720T2 (de) 2007-12-27

Family

ID=22244359

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69935720T Expired - Fee Related DE69935720T2 (de) 1998-07-27 1999-07-22 Diamino-propanol-verbindungen zur behandlung von ischaemien

Country Status (9)

Country Link
US (1) US6511979B1 (de)
EP (1) EP1098642B1 (de)
JP (1) JP2002521435A (de)
AT (1) ATE358473T1 (de)
AU (1) AU756008B2 (de)
CA (1) CA2336549A1 (de)
DE (1) DE69935720T2 (de)
ES (1) ES2285852T3 (de)
WO (1) WO2000006145A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303774B1 (en) 1999-08-20 2001-10-16 Sri International Nucleoside pyrophosphate and triphosphate analogs and related compounds
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1370570B1 (de) * 2001-02-28 2007-01-24 John H. Griffin Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
JP4986335B2 (ja) * 2001-05-15 2012-07-25 生化学工業株式会社 Ｖｄａｃ機能阻害剤
JP5038582B2 (ja) * 2001-07-16 2012-10-03 ジェンザイム・コーポレーション Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2005507919A (ja) * 2001-10-26 2005-03-24 ユニヴァーシティ・テクノロジーズ・インターナショナル・インコーポレーテッド 泌尿生殖器経路の病原感染を阻害するためのｅｇｆの使用
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
EP1734897A4 (de) 2004-03-31 2010-12-22 Merlin Md Pte Ltd Verfahren zur behandlung von aneurysmen
US8500751B2 (en) 2004-03-31 2013-08-06 Merlin Md Pte Ltd Medical device
SG133420A1 (en) * 2005-12-13 2007-07-30 Merlin Md Pte Ltd An endovascular device with membrane having permanently attached agents
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
RU2007110847A (ru) * 2004-08-20 2008-09-27 Де Джонс Хопкинс Юниверсити (US) Способы лечения ангиогенеза
WO2006053043A2 (en) * 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
WO2006057859A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
EP1809202A4 (de) * 2004-12-22 2011-04-27 Merlin Md Pte Ltd Medizinprodukt
WO2007134086A2 (en) * 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
EP2167485B1 (de) 2007-05-31 2015-09-30 Genzyme Corporation Glucosylceramidsynthaseinhibitoren vom 2-acylaminopropoanoltyp
CA2701649C (en) 2007-10-05 2016-05-24 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
EP2320886B1 (de) * 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramid-synthase-hemmung zur behandlung von kollabierender glomerulopathie und anderen glomerulären erkrankungen
CA2738768C (en) 2008-10-03 2017-10-31 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
CA2789517A1 (en) 2010-02-12 2011-08-18 The Johns Hopkins University Use of the lactosylceramide synthase isoform b1,4galt-v as a biomarker for cancer
ES2943709T3 (es) 2012-04-06 2023-06-15 Merlin Md Pte Ltd Dispositivos para tratar un aneurisma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5339567A (en) 1993-06-22 1994-08-23 Pierpont John M Interior-mounted security bars
DE69426331T2 (de) 1993-08-13 2001-06-21 Seikagaku Kogyo Co Ltd Arzneimittel gegen nervöse erkrankungen
EP0765865B1 (de) * 1994-06-10 2001-12-12 Seikagaku Corporation 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide

Also Published As

Publication number Publication date
EP1098642A1 (de) 2001-05-16
AU5224999A (en) 2000-02-21
EP1098642A4 (de) 2004-08-18
CA2336549A1 (en) 2000-02-10
ATE358473T1 (de) 2007-04-15
EP1098642B1 (de) 2007-04-04
AU756008B2 (en) 2003-01-02
DE69935720T2 (de) 2007-12-27
ES2285852T3 (es) 2007-11-16
WO2000006145A1 (en) 2000-02-10
JP2002521435A (ja) 2002-07-16
US6511979B1 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
DE69935720D1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
TW200505900A (en) Muscarinic agonists
ES2194536T3 (es) Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
EA200101166A1 (ru) Ингибиторы металлопротеаз
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
EP1119362A4 (de) Verwendungsmethode von tetracyclinverbindungen zur steigerung der interleukin-10 produktion
DE69021214T2 (de) Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
PT902789E (pt) Derivados de androsteno
ES2173858T3 (es) Analogos de huperzina a.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
ES2099747T3 (es) Aplicacion topica terapeuticamente eficaz de la st1435.
MXPA02004702A (es) Analogos interrumpidos por heteroatomos de acido 15-hidroxieicosatetraenoico y metodos de uso.
DE69727583D1 (de) Vermeidung von gastrointestinaler schädigung
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
BR0012121A (pt) Derivado de aminotetralina para terapia de doenças cardiovasculares
ATE252903T1 (de) Arzneimittel zur behandlung konvulsivischer zustände
WO2001042438A3 (en) Leukolysin/mmp25/mt6-mmp
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
NO950842L (no) Diarylpiperazinoacetamidforbindelser som antimuskariniske midler

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee